Literature DB >> 16585904

[Neuromuscular disorders - assessment of the respiratory muscles].

T Perez1.   

Abstract

Involvement of respiratory muscles is a nearly constant feature of neuromuscular disorders, leading to respiratory failure. A careful respiratory follow up adapted to the variable time course of each disease is therefore mandatory. As the first step, a systematic clinical evaluation is essential to detect the subtle respiratory symptoms and signs related to respiratory muscle failure. Dyspnea and orthopnea are often late findings in patients with a usually severe functional impairment due to peripheral muscle weakness. Nocturnal respiratory events (obstructive sleep apnea syndrome and hypoventilation) are strongly suggested by daytime hypersomnolence and frequent morning headaches. Physical evaluation is essential to detect accessory muscle recruitment, supine abdominal paradox, and encumbrance of upper or lower airways. Vital capacity (VC) is the most classical lung function test. The major limitation of spirometry is its poor sensitivity to detect a moderate inspiratory muscle weakness. Supine VC may improve the detection of diaphragmatic involvement. Peak expiratory flow during cough (cough PEF) gives an overall evaluation of cough efficiency, values below 160 to 270 L/min suggesting poor airway clearance. Arterial blood gases are performed in case of clinical signs, significant deterioration of lung function tests, or sleep desaturations. Hypercapnia is weakly related to lung function results in patients with Steinert dystrophy and those with bulbar involvement. A specific evaluation of respiratory muscle strength is mandatory, as these tests are both sensitive and highly prognostic. Possible discrepancies (particularly in bulbar patients) between maximal inspiratory pressure (PImax) and sniff nasal inspiratory pressure (SNIP) justify to perform both measurements and to select the highest pressure. A maximal expiratory pressure (PEmax) below 45 cm H2O may indicate a compromised cough efficiency but the correlation with cough PEF may be poor. A screening nocturnal oxymetry is useful to detect sleep apneas and hypoventilation. Criteria defining significant desaturations remain however controversial. Suspicion of obstructive sleep apnea syndrome on clinical grounds or oxymetry findings should be confirmed by a conventional polysomnography.

Entities:  

Mesh:

Year:  2006        PMID: 16585904     DOI: 10.1016/s0035-3787(06)75034-2

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  5 in total

1.  Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II.

Authors:  Bruno Bembi; Federica Edith Pisa; Marco Confalonieri; Giovanni Ciana; Agata Fiumara; Rossella Parini; Miriam Rigoldi; Arrigo Moglia; Alfredo Costa; Annalisa Carlucci; Cesare Danesino; Maria Gabriela Pittis; Andrea Dardis; Sabrina Ravaglia
Journal:  J Inherit Metab Dis       Date:  2010-09-14       Impact factor: 4.982

Review 2.  Pathophysiology and clinical evaluation of the patient with unexplained persistent dyspnea.

Authors:  Andi Hudler; Fernando Holguin; Meghan Althoff; Anne Fuhlbrigge; Sunita Sharma
Journal:  Expert Rev Respir Med       Date:  2022-01-20       Impact factor: 4.300

3.  The role of non-invasive ventilation and factors predicting extubation outcome in myasthenic crisis.

Authors:  Jenn-Yu Wu; Ping-Hung Kuo; Pi-Chuan Fan; Huey-Dong Wu; Fuh-Yuan Shih; Pan-Chyr Yang
Journal:  Neurocrit Care       Date:  2008-09-20       Impact factor: 3.210

4.  Skeletal muscle-specific calpastatin overexpression mitigates muscle weakness in aging and extends life span.

Authors:  Elizabeth A Schroder; Lin Wang; Yuan Wen; Leigh Ann P Callahan; Gerald S Supinski
Journal:  J Appl Physiol (1985)       Date:  2021-07-01

5.  Individualized supervised resistance training during nebulization in adults with cystic fibrosis.

Authors:  Ina Shaw; Janine E Kinsey; Roxanne Richards; Brandon S Shaw
Journal:  Pak J Med Sci       Date:  2016 Sep-Oct       Impact factor: 1.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.